To ascertain the differential expression and prognostic significance of MAP7D3 in prostate adenocarcinoma (PRAD), we conducted immunohistochemistry experiments on 60 PRAD samples and their corresponding normal prostate tissue samples. This evidence concerns the gene MAP7D3 and prostate adenocarcinoma.